Scantox Group Acquires Gentronix Ltd
September 9, 2024
Scantox Group, together with its majority owner Impilo, has acquired Gentronix Ltd, a UK-based GLP-compliant genetic toxicology CRO headquartered at Alderley Park. The acquisition expands Scantox's preclinical service platform by adding specialist genetic, skin and ocular toxicology capabilities, bringing the Scantox Group to more than 400 employees across seven European sites.
- Buyers
- Scantox Group, Impilo
- Targets
- Gentronix Ltd
- Platforms
- Scantox Group
- Industry
- Healthcare Services
- Location
- Cheshire, United Kingdom
- Transaction Type
- Addon
Explore More
Related Acquisitions
-
Scantox Group Acquires TwinStrand Biosciences DuplexSeq Nonclinical Genomics Safety Business
February 26, 2026
Healthcare Services
Scantox Group acquired TwinStrand Biosciences’ nonclinical genomic safety business through a technology transfer and license agreement. The deal grants Scantox rights to be the sole global provider of DuplexSeq Mutagenesis Assays and related nonclinical genomics safety services, integrating them into Scantox’s existing genetic toxicology platform.
-
Aragen Life Sciences Acquires INTOX Pvt. Ltd.
December 15, 2021
Healthcare Services
Aragen Life Sciences, a global CRO/CDMO, signed a definitive agreement to acquire Pune-based INTOX Pvt. Ltd. The deal adds GLP-certified safety assessment capabilities to strengthen Aragen’s integrated discovery-to-development platform for pharmaceuticals, biotechnology, animal health, and agrochemicals.
-
Discovery Life Sciences Acquires Gentest Business from Corning Incorporated
April 5, 2022
Biotechnology
Discovery Life Sciences has acquired the Gentest business unit from Corning Incorporated to expand its in vitro ADME and toxicology reagent and services offering. The deal complements Discovery’s recent acquisition of In Vitro ADMET Laboratories (IVAL) and strengthens its hepatocyte, microsome and ADME-related product and contracted research capabilities for pharmaceutical and life sciences customers.
-
Labcorp Acquires Toxikon Corporation
November 18, 2021
Healthcare Services
Labcorp has acquired Toxikon Corporation, a Bedford, Massachusetts-based contract research organization that provides nonclinical in vivo and in vitro testing for pharmaceutical, biotech and medical device clients. The acquisition expands Labcorp Drug Development's nonclinical testing capabilities and creates a strategic Boston-area footprint; Toxikon reported approximately $40 million in annual revenue and the deal closed in December 2021.
-
Charles River Laboratories Acquires Retrogenix
March 31, 2021
Biotechnology
Charles River Laboratories has acquired Retrogenix Limited, a UK-based contract research organization specializing in cell microarray technology for target receptor identification and off-target profiling. The transaction was for approximately £35 million in cash with up to an additional £5 million contingent on performance, and Retrogenix becomes part of Charles River's Discovery and Safety Assessment segment to expand large-molecule and cell therapy discovery capabilities.
-
3E Acquires Toxnot
December 12, 2022
Cloud & SaaS
3E, a global provider of EHS&S and product compliance solutions, acquired Toxnot, a SaaS platform for product compliance and supply chain sustainability. The acquisition expands 3E's supply chain transparency and sustainability capabilities by integrating Toxnot's digital product passport and supplier data-sharing technology into its compliance suite.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.